Blueprint Medicines Corp AYVAKIT™ FDA Approval Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines AYVAKIT FDA Approval Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Please go ahead.
Thank you, operator. Good afternoon, everyone. This is Kristin Hodous of Blueprint Medicines, and welcome to our conference call to discuss the FDA approval of AYVAKIT. You can access our press release announcing the approval as well as the slides we'll be reviewing today by going to the investors & media section of our website at www.blueprintmedicines.com. With me on the call today are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christina Rossi, our Chief Commercial Officer.
Before we get started,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |